Alnylam Pharmaceuticals (ALNY) is a leader in the field of RNAI Therapies, says a Cowen analyst. Ritu Baral discusses the outlook for the biotech sector in 2023. She also talks about Sarepta Therapeutics (SRPT). The Cowen analyst notes that they now say the probability that SRP-9001 will receive approval. She goes over how Cowen has an outperform rating on SRPT and a $125 price target. Finally, she mentions how SRPT releases 4Q earnings, Tuesday, February 28th. Tune in to find out more about the stock market today.
24 Feb 2023
The Watch List
31 Jan 2023
The Watch List
17 Feb 2023
The Watch List
22 Jan 2023
Market On Close
23 Jan 2023
Morning Trade Live
18 Jan 2023
Trading 360
13 Jan 2023